EP0819129B1
(de)
*
|
1995-04-03 |
2000-08-02 |
Novartis AG |
Pyrazolderivate und verfahren zu deren herstellung
|
JP4242928B2
(ja)
|
1996-08-23 |
2009-03-25 |
ノバルティス アクチエンゲゼルシャフト |
置換ピロロピリミジンおよびその製造方法
|
DE69825066T2
(de)
|
1997-02-07 |
2005-08-25 |
Princeton University |
Gentechnisch hergestellte Proteinkinasen, welche modifizierte Nukleotidtriphosphatsubstrate verwenden können
|
CA2360740A1
(en)
|
1999-03-02 |
2000-09-08 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compounds useful as reversible inhibitors of cathepsin s
|
US6440959B1
(en)
|
1999-04-21 |
2002-08-27 |
Hoffman-La Roche Inc. |
Pyrazolobenzodiazepines
|
US6610483B1
(en)
*
|
1999-07-23 |
2003-08-26 |
Princeton University |
Methods for identifying cellular responses attributable to signaling molecule inhibition and inhibitors thereof
|
US6420364B1
(en)
|
1999-09-13 |
2002-07-16 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Compound useful as reversible inhibitors of cysteine proteases
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
US6613776B2
(en)
|
2000-09-15 |
2003-09-02 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
AU2001292670A1
(en)
|
2000-09-15 |
2002-03-26 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
SI1318997T1
(sl)
*
|
2000-09-15 |
2006-12-31 |
Vertex Pharma |
Pirazolne spojine, uporabne kot inhibitorji protein-kinaze
|
BR0116411A
(pt)
|
2000-12-21 |
2003-11-11 |
Vertex Pharma |
Compostos de pirazol úteis como inibidores de proteìna cinase
|
US6593349B2
(en)
*
|
2001-03-19 |
2003-07-15 |
Icagen, Inc. |
Bisarylamines as potassium channel openers
|
US20050119251A1
(en)
*
|
2001-12-21 |
2005-06-02 |
Jian-Min Fu |
Nicotinamide derivatives and their use as therapeutic agents
|
MY141867A
(en)
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
AU2003250701A1
(en)
*
|
2002-07-31 |
2004-02-16 |
Wayne R. Danter |
Protein tyrosine kinase inhibitors
|
DE60318089T2
(de)
*
|
2002-10-09 |
2008-12-04 |
Critical Outcome Technologies, Inc. |
Protein-tyrosine-kinase-inhibitoren
|
WO2005020921A2
(en)
*
|
2003-08-29 |
2005-03-10 |
Exelixis, Inc. |
C-kit modulators and methods of use
|
US20050165029A1
(en)
*
|
2004-01-13 |
2005-07-28 |
Ambit Biosciences Corporation |
Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
|
CN101083994A
(zh)
|
2004-09-20 |
2007-12-05 |
泽农医药公司 |
杂环衍生物及其用作硬脂酰CoA去饱和酶抑制剂的用途
|
CA2580845A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
|
AR051202A1
(es)
|
2004-09-20 |
2006-12-27 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
|
MX2007003321A
(es)
|
2004-09-20 |
2007-06-05 |
Xenon Pharmaceuticals Inc |
Derivados heterociclicos y su uso como agentes terapeuticos.
|
AU2005329423A1
(en)
|
2004-09-20 |
2006-09-28 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
WO2006034312A1
(en)
*
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coa-desaturase (scd)
|
US7951805B2
(en)
|
2004-09-20 |
2011-05-31 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
|
WO2006034315A2
(en)
*
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
RU2349319C1
(ru)
*
|
2004-11-18 |
2009-03-20 |
Бристол-Маерс Сквибб Компани |
Гранула, покрытая энтеросолюбильной оболочкой, содержащая иксабепилон, и способ ее приготовления
|
JP2008520744A
(ja)
*
|
2004-11-19 |
2008-06-19 |
ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア |
抗炎症性ピラゾロピリミジン
|
DE602005026865D1
(de)
*
|
2004-12-14 |
2011-04-21 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
BRPI0611187A2
(pt)
|
2005-06-03 |
2010-08-24 |
Xenon Pharmaceuticals Inc |
derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
|
CN101316843B
(zh)
|
2005-11-03 |
2013-01-02 |
顶点医药品公司 |
用作激酶抑制剂的氨基嘧啶
|
AU2007224020A1
(en)
*
|
2006-03-07 |
2007-09-13 |
Array Biopharma Inc. |
Heterobicyclic pyrazole compounds and methods of use
|
KR20090077914A
(ko)
*
|
2006-09-11 |
2009-07-16 |
쿠리스 인코퍼레이션 |
항증식제로서의 다작용성 소분자
|
US20080161320A1
(en)
*
|
2006-09-11 |
2008-07-03 |
Xiong Cai |
Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
|
EP2123654A4
(de)
*
|
2006-12-28 |
2011-05-11 |
Taisho Pharmaceutical Co Ltd |
Pyrazolopyrimidinverbindung
|
US8034815B2
(en)
|
2007-01-11 |
2011-10-11 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
EP1969935A1
(de)
*
|
2007-03-12 |
2008-09-17 |
Bayer CropScience AG |
3,4-Disubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide
|
EP1969934A1
(de)
*
|
2007-03-12 |
2008-09-17 |
Bayer CropScience AG |
4-Cycloalkyl-oder 4-arylsubstituierte Phenoxyphenylamidine und deren Verwendung als Fungizide
|
EP1969933A1
(de)
*
|
2007-03-12 |
2008-09-17 |
Bayer CropScience AG |
Dihalogenphenoxyphenylamidine und deren Verwendung als Fungizide
|
US20100167926A1
(en)
|
2007-03-12 |
2010-07-01 |
Bayer Cropscience Ag |
3-substituted phenoxyphenylamidines and use thereof as fungicides
|
JP2010520899A
(ja)
*
|
2007-03-12 |
2010-06-17 |
バイエル・クロツプサイエンス・アクチエンゲゼルシヤフト |
ジハロフェノキシフェニルアミジン及び殺真菌剤としてのその使用
|
EP1969932A1
(de)
*
|
2007-03-12 |
2008-09-17 |
Bayer CropScience AG |
Phenoxyphenylamidine und deren Verwendung als Fungizide
|
EP2120558B1
(de)
*
|
2007-03-12 |
2016-02-10 |
Bayer Intellectual Property GmbH |
3,4-Disubstituierte Phenoxyphenylamidin-Derivate und deren Verwendung als Fungizide
|
AU2008247592A1
(en)
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
AU2008282156B2
(en)
|
2007-07-31 |
2014-07-17 |
Vertex Pharmaceuticals Incorporated |
Process for preparing 5-fluoro-1H-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
WO2009046448A1
(en)
|
2007-10-04 |
2009-04-09 |
Intellikine, Inc. |
Chemical entities and therapeutic uses thereof
|
CA2710039C
(en)
|
2007-12-26 |
2018-07-03 |
Critical Outcome Technologies, Inc. |
Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
|
US8637542B2
(en)
|
2008-03-14 |
2014-01-28 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
JP5260114B2
(ja)
*
|
2008-03-31 |
2013-08-14 |
株式会社カネカ |
N−アルコキシカルボニル−tert−ロイシンの製造法
|
WO2010006086A2
(en)
|
2008-07-08 |
2010-01-14 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
CA2730890C
(en)
|
2008-07-17 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
AU2009288200A1
(en)
|
2008-09-03 |
2010-03-11 |
Vertex Pharmaceuticals Incorporated |
Co-crystals and pharmaceutical formulations comprising the same
|
US8476431B2
(en)
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
WO2010099137A2
(en)
|
2009-02-26 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
In situ methods for monitoring the emt status of tumor cells in vivo
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010099363A1
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
US20120064072A1
(en)
|
2009-03-18 |
2012-03-15 |
Maryland Franklin |
Combination Cancer Therapy Comprising Administration of an EGFR Inhibitor and an IGF-1R Inhibitor
|
KR20120026024A
(ko)
|
2009-04-24 |
2012-03-16 |
가부시키가이샤 가네카 |
N-알콕시카르보닐-tert-류신의 제조법
|
JP5819831B2
(ja)
|
2009-08-17 |
2015-11-24 |
インテリカイン, エルエルシー |
複素環式化合物およびそれらの使用
|
US20120316187A1
(en)
|
2009-11-13 |
2012-12-13 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer
|
US8987272B2
(en)
|
2010-04-01 |
2015-03-24 |
Critical Outcome Technologies Inc. |
Compounds and method for treatment of HIV
|
EP2468883A1
(de)
|
2010-12-22 |
2012-06-27 |
Pangaea Biotech S.L. |
Molekulare Biomarker zur Vorhersage der Reaktion auf Tyrosinkinaseinhibitoren bei Lungenkrebs
|
US9134297B2
(en)
|
2011-01-11 |
2015-09-15 |
Icahn School Of Medicine At Mount Sinai |
Method and compositions for treating cancer and related methods
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
EP2492688A1
(de)
|
2011-02-23 |
2012-08-29 |
Pangaea Biotech, S.A. |
Molekulare Biomarker zur Vorhersage der Reaktion auf die Antitumorbehandlung bei Lungenkrebs
|
WO2012129145A1
(en)
|
2011-03-18 |
2012-09-27 |
OSI Pharmaceuticals, LLC |
Nscle combination therapy
|
WO2012149014A1
(en)
|
2011-04-25 |
2012-11-01 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
JP6297490B2
(ja)
|
2011-08-31 |
2018-03-20 |
ジェネンテック, インコーポレイテッド |
診断マーカー
|
WO2013038390A1
(en)
|
2011-09-16 |
2013-03-21 |
Novartis Ag |
N-substituted heterocyclyl carboxamides
|
WO2013055530A1
(en)
|
2011-09-30 |
2013-04-18 |
Genentech, Inc. |
Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN103483242A
(zh)
*
|
2012-06-15 |
2014-01-01 |
上海朴颐化学科技有限公司 |
4-(2’-吡啶基)苄基肼及其中间体的制备方法
|
WO2013190089A1
(en)
|
2012-06-21 |
2013-12-27 |
Pangaea Biotech, S.L. |
Molecular biomarkers for predicting outcome in lung cancer
|
EP2976085A1
(de)
|
2013-03-21 |
2016-01-27 |
INSERM - Institut National de la Santé et de la Recherche Médicale |
Verfahren und pharmazeutische zusammensetzung zur verwendung bei der behandlung von chronischen lebererkrankungen im zusammenhang mit einer niedrigen hepcidinexpression
|
CN105209042B
(zh)
|
2013-03-22 |
2019-03-08 |
米伦纽姆医药公司 |
催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
|
CN103709044A
(zh)
*
|
2013-12-12 |
2014-04-09 |
江苏集贤绿色化学科技研究院有限公司 |
一种3-氯-4-氟苯胺盐酸盐的制备方法
|
WO2015156674A2
(en)
|
2014-04-10 |
2015-10-15 |
Stichting Het Nederlands Kanker Instituut |
Method for treating cancer
|
TW201613919A
(en)
*
|
2014-07-02 |
2016-04-16 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
MX2017008421A
(es)
|
2014-12-24 |
2018-03-23 |
Genentech Inc |
Métodos terapéuticos, diagnósticos y pronósticos para el cáncer de vejiga.
|
WO2017035354A1
(en)
|
2015-08-26 |
2017-03-02 |
Blueprint Medicines Corporation |
Compounds and compositions useful for treating disorders related to ntrk
|
RU2018122089A
(ru)
|
2015-11-19 |
2019-12-25 |
Блюпринт Медсинс Корпорейшн |
Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk
|
CN108101811A
(zh)
|
2016-11-25 |
2018-06-01 |
斯福瑞(南通)制药有限公司 |
生产n-叔丁氧羰基-2-氨基-3,3-二甲基丁酸的方法
|
RS62456B1
(sr)
|
2016-12-22 |
2021-11-30 |
Amgen Inc |
Derivati benzizotiazola, izotiazolo[3,4-b]piridina, hinazolina, ftalazina, pirido[2,3-d]piridazina i pirido[2,3-d]pirimidina kao kras g12c inhibitori za tretman raka pluća, pankreasa ili debelog creva
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
SG11202001499WA
(en)
|
2017-09-08 |
2020-03-30 |
Amgen Inc |
Inhibitors of kras g12c and methods of using the same
|
US11045484B2
(en)
|
2018-05-04 |
2021-06-29 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP3788038B1
(de)
|
2018-05-04 |
2023-10-11 |
Amgen Inc. |
Kras-g12c-inhibitoren und verfahren zu deren verwendung
|
WO2019217691A1
(en)
|
2018-05-10 |
2019-11-14 |
Amgen Inc. |
Kras g12c inhibitors for the treatment of cancer
|
US11096939B2
(en)
|
2018-06-01 |
2021-08-24 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
EP3802537A1
(de)
|
2018-06-11 |
2021-04-14 |
Amgen Inc. |
Kras-g12c-inhibitoren zur behandlung von krebs
|
MX2020012261A
(es)
|
2018-06-12 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
|
US20210393632A1
(en)
|
2018-10-04 |
2021-12-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Egfr inhibitors for treating keratodermas
|
JP2020090482A
(ja)
|
2018-11-16 |
2020-06-11 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
CA3117222A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
MA54547A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
ES2953821T3
(es)
|
2018-12-20 |
2023-11-16 |
Amgen Inc |
Inhibidores de KIF18A
|
MA54546A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
|
PE20211475A1
(es)
|
2018-12-20 |
2021-08-05 |
Amgen Inc |
Inhibidores de kif18a
|
US20230096028A1
(en)
|
2019-03-01 |
2023-03-30 |
Revolution Medicines, Inc. |
Bicyclic heterocyclyl compounds and uses thereof
|
JP2022522777A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロアリール化合物及びその使用
|
EP3738593A1
(de)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosierung von kras-inhibitor zur behandlung von krebserkrankungen
|
EP3972973A1
(de)
|
2019-05-21 |
2022-03-30 |
Amgen Inc. |
Festkörperformen
|
US20220372018A1
(en)
|
2019-08-02 |
2022-11-24 |
Amgen Inc. |
Kif18a inhibitors
|
AU2020324963A1
(en)
|
2019-08-02 |
2022-02-24 |
Amgen Inc. |
KIF18A inhibitors
|
CN114401953A
(zh)
|
2019-08-02 |
2022-04-26 |
美国安进公司 |
Kif18a抑制剂
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021081212A1
(en)
|
2019-10-24 |
2021-04-29 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
TW202132314A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ras抑制劑
|
CA3159559A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
EP4054719A1
(de)
|
2019-11-04 |
2022-09-14 |
Revolution Medicines, Inc. |
Ras-inhibitoren
|
PE20230249A1
(es)
|
2019-11-08 |
2023-02-07 |
Revolution Medicines Inc |
Compuestos de heteroarilo biciclicos y usos de estos
|
WO2021097212A1
(en)
|
2019-11-14 |
2021-05-20 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
AR120456A1
(es)
|
2019-11-14 |
2022-02-16 |
Amgen Inc |
Síntesis mejorada del compuesto inhibidor de g12c de kras
|
JP2023505100A
(ja)
|
2019-11-27 |
2023-02-08 |
レボリューション メディシンズ インコーポレイテッド |
共有ras阻害剤及びその使用
|
BR112022010086A2
(pt)
|
2020-01-07 |
2022-09-06 |
Revolution Medicines Inc |
Dosagem do inibidor de shp2 e métodos de tratamento de câncer
|
CN115916194A
(zh)
|
2020-06-18 |
2023-04-04 |
锐新医药公司 |
用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
KR20230067635A
(ko)
|
2020-09-15 |
2023-05-16 |
레볼루션 메디슨즈, 인크. |
암의 치료에서 ras 억제제로서 인돌 유도체
|
CN117396472A
(zh)
|
2020-12-22 |
2024-01-12 |
上海齐鲁锐格医药研发有限公司 |
Sos1抑制剂及其用途
|
CR20230570A
(es)
|
2021-05-05 |
2024-01-22 |
Revolution Medicines Inc |
Inhibidores de ras
|
CN117500811A
(zh)
|
2021-05-05 |
2024-02-02 |
锐新医药公司 |
共价ras抑制剂及其用途
|
WO2022235870A1
(en)
|
2021-05-05 |
2022-11-10 |
Revolution Medicines, Inc. |
Ras inhibitors for the treatment of cancer
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
TW202340214A
(zh)
|
2021-12-17 |
2023-10-16 |
美商健臻公司 |
做為shp2抑制劑之吡唑并吡𠯤化合物
|
EP4227307A1
(de)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazinverbindungen als shp2-inhibitoren
|
WO2023172940A1
(en)
|
2022-03-08 |
2023-09-14 |
Revolution Medicines, Inc. |
Methods for treating immune refractory lung cancer
|
WO2023240263A1
(en)
|
2022-06-10 |
2023-12-14 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
WO2024081916A1
(en)
|
2022-10-14 |
2024-04-18 |
Black Diamond Therapeutics, Inc. |
Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
|